Literature DB >> 31513387

Design and Synthesis of Fungal-Selective Resorcylate Aminopyrazole Hsp90 Inhibitors.

David S Huang1, Emmanuelle V LeBlanc2, Tanvi Shekhar-Guturja2, Nicole Robbins2, Damian J Krysan3, Juan Pizarro4, Luke Whitesell2, Leah E Cowen2, Lauren E Brown1.   

Abstract

The molecular chaperone Hsp90, essential in all eukaryotes, plays a multifaceted role in promoting survival, virulence, and drug resistance across diverse pathogenic fungal species. The chaperone is also critically important, however, to the pathogen's human host, preventing the use of known clinical Hsp90 inhibitors in antifungal applications due to concomitant host toxicity issues. With the goal of developing Hsp90 inhibitors with acceptable therapeutic indices for the treatment of invasive fungal infections, we initiated a program to design and synthesize potent inhibitors with selective activity against fungal Hsp90 isoforms over their human counterparts. Building on our previously reported derivatization of resorcylate natural products to produce fungal-selective compounds, we have developed a series of synthetic aminopyrazole-substituted resorcylate amides with broad, potent, and fungal-selective Hsp90 inhibitory activity. Herein we describe the synthesis of this series, as well as biochemical structure-activity relationships driving selectivity for the Hsp90 isoforms expressed by Cryptococcus neoformans and Candida albicans, two pathogenic fungi of major clinical importance.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31513387      PMCID: PMC7069776          DOI: 10.1021/acs.jmedchem.9b00826

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  59 in total

1.  Development of a Grp94 inhibitor.

Authors:  Adam S Duerfeldt; Laura B Peterson; Jason C Maynard; Chun Leung Ng; Davide Eletto; Olga Ostrovsky; Heather E Shinogle; David S Moore; Yair Argon; Christopher V Nicchitta; Brian S J Blagg
Journal:  J Am Chem Soc       Date:  2012-05-29       Impact factor: 15.419

2.  Paralog-selective Hsp90 inhibitors define tumor-specific regulation of HER2.

Authors:  Pallav D Patel; Pengrong Yan; Paul M Seidler; Hardik J Patel; Weilin Sun; Chenghua Yang; Nanette S Que; Tony Taldone; Paola Finotti; Ralph A Stephani; Daniel T Gewirth; Gabriela Chiosis
Journal:  Nat Chem Biol       Date:  2013-09-01       Impact factor: 15.040

3.  Identification of novel HSP90α/β isoform selective inhibitors using structure-based drug design. demonstration of potential utility in treating CNS disorders such as Huntington's disease.

Authors:  Justin T Ernst; Timothy Neubert; Michael Liu; Samuel Sperry; Harmon Zuccola; Amy Turnbull; Beth Fleck; William Kargo; Lisa Woody; Peggy Chiang; Dao Tran; Weichao Chen; Phillip Snyder; Timothy Alcacio; Azin Nezami; James Reynolds; Khisal Alvi; Lance Goulet; Dean Stamos
Journal:  J Med Chem       Date:  2014-04-10       Impact factor: 7.446

4.  New molecular and biological mechanism of antitumor activities of KW-2478, a novel nonansamycin heat shock protein 90 inhibitor, in multiple myeloma cells.

Authors:  Takayuki Nakashima; Toshihiko Ishii; Hisashi Tagaya; Toshihiro Seike; Hiroshi Nakagawa; Yutaka Kanda; Shiro Akinaga; Shiro Soga; Yukimasa Shiotsu
Journal:  Clin Cancer Res       Date:  2010-04-20       Impact factor: 12.531

5.  Phase I study of the heat shock protein 90 (Hsp90) inhibitor onalespib (AT13387) administered on a daily for 2 consecutive days per week dosing schedule in patients with advanced solid tumors.

Authors:  Khanh Do; Giovanna Speranza; Lun-Ching Chang; Eric C Polley; Rachel Bishop; Weimin Zhu; Jane B Trepel; Sunmin Lee; Min-Jung Lee; Robert J Kinders; Larry Phillips; Jerry Collins; John Lyons; Woondong Jeong; Ramya Antony; Alice P Chen; Len Neckers; James H Doroshow; Shivaani Kummar
Journal:  Invest New Drugs       Date:  2015-06-18       Impact factor: 3.850

6.  A Phase 2 Study of the Hsp90 Inhibitor AUY922 as Treatment for Patients with Refractory Gastrointestinal Stromal Tumors.

Authors:  Johanna C Bendell; Todd M Bauer; Ruth Lamar; Mathew Joseph; William Penley; Dana S Thompson; David R Spigel; Rami Owera; Cassie M Lane; Chris Earwood; Howard A Burris
Journal:  Cancer Invest       Date:  2016-07-05       Impact factor: 2.176

7.  Initial testing (stage 1) of ganetespib, an Hsp90 inhibitor, by the Pediatric Preclinical Testing Program.

Authors:  Richard B Lock; Hernan Carol; John M Maris; Min H Kang; C Patrick Reynolds; E Anders Kolb; Richard Gorlick; Stephen T Keir; Catherine A Billups; Raushan T Kurmasheva; Peter J Houghton; Malcolm A Smith
Journal:  Pediatr Blood Cancer       Date:  2013-01-09       Impact factor: 3.167

Review 8.  Paralog Specific Hsp90 Inhibitors - A Brief History and a Bright Future.

Authors:  Daniel T Gewirth
Journal:  Curr Top Med Chem       Date:  2016       Impact factor: 3.295

9.  Anti-tumor activity against multiple myeloma by combination of KW-2478, an Hsp90 inhibitor, with bortezomib.

Authors:  T Ishii; T Seike; T Nakashima; S Juliger; L Maharaj; S Soga; S Akinaga; J Cavenagh; S Joel; Y Shiotsu
Journal:  Blood Cancer J       Date:  2012-04-27       Impact factor: 11.037

10.  NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models.

Authors:  Michael Rugaard Jensen; Joseph Schoepfer; Thomas Radimerski; Andrew Massey; Chantale T Guy; Josef Brueggen; Cornelia Quadt; Alan Buckler; Robert Cozens; Martin J Drysdale; Carlos Garcia-Echeverria; Patrick Chène
Journal:  Breast Cancer Res       Date:  2008-04-22       Impact factor: 6.466

View more
  11 in total

Review 1.  Novel Promising Antifungal Target Proteins for Conquering Invasive Fungal Infections.

Authors:  Cheng Zhen; Hui Lu; Yuanying Jiang
Journal:  Front Microbiol       Date:  2022-06-16       Impact factor: 6.064

Review 2.  Structure-guided approaches to targeting stress responses in human fungal pathogens.

Authors:  Emmanuelle V LeBlanc; Elizabeth J Polvi; Amanda O Veri; Gilbert G Privé; Leah E Cowen
Journal:  J Biol Chem       Date:  2020-08-12       Impact factor: 5.157

3.  Fungal-Selective Resorcylate Aminopyrazole Hsp90 Inhibitors: Optimization of Whole-Cell Anticryptococcal Activity and Insights into the Structural Origins of Cryptococcal Selectivity.

Authors:  Paul T Marcyk; Emmanuelle V LeBlanc; Douglas A Kuntz; Alice Xue; Francisco Ortiz; Richard Trilles; Stephen Bengtson; Tristan M G Kenney; David S Huang; Nicole Robbins; Noelle S Williams; Damian J Krysan; Gilbert G Privé; Luke Whitesell; Leah E Cowen; Lauren E Brown
Journal:  J Med Chem       Date:  2021-01-14       Impact factor: 7.446

Review 4.  Antifungal Drug Resistance: Molecular Mechanisms in Candida albicans and Beyond.

Authors:  Yunjin Lee; Emily Puumala; Nicole Robbins; Leah E Cowen
Journal:  Chem Rev       Date:  2020-05-22       Impact factor: 60.622

5.  Fluorescence Polarization-Based Measurement of Protein-Ligand Interaction in Fungal Cell Lysates.

Authors:  Emmanuelle V LeBlanc; Tanvi Shekhar-Guturja; Luke Whitesell; Leah E Cowen
Journal:  Curr Protoc       Date:  2021-01

6.  The Proteasome Governs Fungal Morphogenesis via Functional Connections with Hsp90 and cAMP-Protein Kinase A Signaling.

Authors:  Saif Hossain; Amanda O Veri; Leah E Cowen
Journal:  mBio       Date:  2020-04-21       Impact factor: 7.867

Review 7.  Treatment strategies for cryptococcal infection: challenges, advances and future outlook.

Authors:  Kali R Iyer; Nicole M Revie; Ci Fu; Nicole Robbins; Leah E Cowen
Journal:  Nat Rev Microbiol       Date:  2021-02-08       Impact factor: 60.633

Review 8.  The role of Candida albicans stress response pathways in antifungal tolerance and resistance.

Authors:  Kali R Iyer; Nicole Robbins; Leah E Cowen
Journal:  iScience       Date:  2022-02-19

Review 9.  Chaperone Networks in Fungal Pathogens of Humans.

Authors:  Linda C Horianopoulos; James W Kronstad
Journal:  J Fungi (Basel)       Date:  2021-03-12

10.  Effects of Hsp90 Inhibitor Ganetespib on Inhibition of Azole-Resistant Candida albicans.

Authors:  Rui Yuan; Jie Tu; Chunquan Sheng; Xi Chen; Na Liu
Journal:  Front Microbiol       Date:  2021-05-20       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.